WallStSmart

Brainsway Ltd (BWAY)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 39393% more annual revenue ($20.63B vs $52.23M). BWAY leads profitability with a 14.6% profit margin vs 10.1%. GEHC trades at a lower P/E of 15.6x. GEHC earns a higher WallStSmart Score of 60/100 (C+).

BWAY

Hold

46

out of 100

Grade: D+

Growth: 7.3Profit: 5.5Value: 3.0Quality: 5.0

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BWAYSignificantly Overvalued (-178.3%)

Margin of Safety

-178.3%

Fair Value

$8.42

Current Price

$13.50

$5.08 premium

UndervaluedFair: $8.42Overvalued
GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BWAY1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
27.4%8/10

Revenue surging 27.4% year-over-year

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

BWAY4 concerns · Avg: 2.8/10
EPS GrowthGrowth
3.9%4/10

3.9% earnings growth

Market CapQuality
$536.38M3/10

Smaller company, higher risk/reward

P/E RatioValuation
75.9x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-2.02M2/10

Negative free cash flow — burning cash

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BWAY

The strongest argument for BWAY centers on Revenue Growth. Revenue growth of 27.4% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : BWAY

The primary concerns for BWAY are EPS Growth, Market Cap, P/E Ratio. A P/E of 75.9x leaves little room for execution misses.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

BWAY profiles as a growth stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

BWAY is growing revenue faster at 27.4% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 46/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brainsway Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?